UPDATE: Morgan Stanley Initiates Quintiles Transnational at Overweight on CRO Market Leader Position
In a report published Tuesday, Morgan Stanley analyst Ricky R. Goldwasser initiated coverage on Quintiles Transnational (NYSE: Q) with an Overweight rating and $51.00 price target.
In the report, Morgan Stanley noted, “As the contract research organization (CRO) market leader with 11% share of clinical outsourcing, a diversified customer base and backlog visibility, we believe Quintiles is best positioned to benefit from the growth in biopharmaceutical R&D outsourcing.”
Quintiles Transnational closed on Monday at $43.53.
Latest Ratings for Q
|Feb 2017||Deutsche Bank||Downgrades||Buy||Hold|
|Dec 2016||Goldman Sachs||Downgrades||Buy||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.